Linepemat
Pharmaceutical compound
Linepemat, also known as 3-(2,3-difluorophenoxy)azetidine, is a drug described as a "nootrope". It has been found to produce hyperlocomotion in rodents as well as to dose-dependently reverse the hypolocomotion induced by the monoamine depleting agent tetrabenazine in rodents. The drug was patented by Integrative Research Laboratories (IRL) in January 2025 with the application of treatment of apathy and its INNTooltip International Nonproprietary Name was registered in January 2026. IRL is developing a drug with the developmental code name IRL757 for treatment of apathy in Parkinson's disease and neurodegenerative disorders. As of January 2026, IRL757 is in phase 1/2 clinical trials for Parkinson's disease and phase 1 trials for neurodegenerative disorders, having entered phase 1/2 trials by December 2025. Linepemat is very similar in chemical structure to pirepemat (IRL752), another nootropic drug candidate.
Begin with the source’s own compact description: “Linepemat” is pharmaceutical compound. The dossier treats that line as a proposition to test through Linepemat, Pharmaceutical and compound, not as a finished interpretation.
Why this record matters
The phrase “pharmaceutical compound” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Aug 18, 2026. The first chronological checks are 2025 and 2026.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Linepemat”, its source revision and the description used here.
- Expand the search: follow Linepemat primary sources, Linepemat archive and Linepemat research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Linepemat”?
- Which institution is responsible for the underlying evidence?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Linepemat” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.